ReviewThrombosis and haemostasis2013
Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles.
Review in Thrombosis and haemostasis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04116164 (A Phase 0 Study to Assess the Safety and Biodistribution of a Novel Radiolabeled Antibody Targeting Human Kallikrein-2), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 0 Study to Assess the Safety and Biodistribution of a Novel Radiolabeled Antibody Targeting Human Kallikrein-2 (hk2) in Subjects With Metastatic Castration-resistant Prostate Cancer.
Who cites it
24 citing papers in PubMed, 58 citations in OpenAlex.
- Urine cell-free RNA for bladder cancer detection and treatment response prediction.Nature medicine · 2026Article
- Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.Nature communications · 2026Article
- Drug Discovery Strategies for Kallikrein-Related Peptidases.International journal of molecular sciences · 2025Review
- Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Long-Term Exposure to Supraphysiological Levels of Testosterone Impacts Rat Submandibular Gland Proteome.International journal of molecular sciences · 2023Article
- Designed ankyrin repeat proteins for detecting prostate-specific antigen expressionRSC chemical biology · 2023Article
- Novel radionuclide therapy combinations in prostate cancer.Therapeutic advances in medical oncology · 2023Review
- Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states.Nature communications · 2022Article
- Identification of Androgen Receptor Metabolic Correlome Reveals the Repression of Ceramide Kinase by Androgens.Cancers · 2021Article
- Prostate-specific antigen modulates the osteogenic differentiation of MSCs via the cadherin 11-Akt axis.Clinical and translational medicine · 2020Article
- Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Molecular Biomarkers in the Clinical Management of Prostate Cancer.Cold Spring Harbor perspectives in medicine · 2018Review
- Tumour biomarkers: homeostasis as a novel prognostic indicator.Open biology · 2016Review
- Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.Science translational medicine · 2016Article
- The role of the prostate in male fertility, health and disease.Nature reviews. Urology · 2016Review
- A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer.Cancer discovery · 2015Article
- Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution.Nuclear medicine and biology · 2015Article
- Protease-activated pore-forming peptides for the treatment and imaging of prostate cancer.Molecular cancer therapeutics · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Kallikreins are a family of serine proteases with a range of tissue-specific and essential proteolytic functions. Among the best studied are the prostate tissue-specific KLK2 and KLK3 genes and their secreted protease products, human kallikrein 2, hk2, and prostate-specific antigen (PSA). Members of the so-called classic kallikreins, these highly active trypsin-like serine proteases play established roles in human reproduction. Both hK2 and PSA expression is regulated by the androgen receptor which has a fundamental role in prostate tissue development and progression of disease. This feature, combined with the ability to sensitively detect different forms of these proteins in blood and biopsies, result in a crucially important biomarker for the presence and recurrence of cancer. Emerging evidence has begun to suggest a role for these kallikreins in critical vascular events. This review discusses the established and developing biological roles of hK2 and PSA, as well as the historical and advanced use of their detection to accurately and non-invasively detect and guide treatment of prostatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.